BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37931433)

  • 1. Canine immune cells express high levels of CB
    Brown C; Mitsch M; Blankenship K; Campbell C; Pelanne M; Sears J; Bell A; Olivier AK; Ross MK; Archer T; Kaplan BLF
    Vet Immunol Immunopathol; 2023 Nov; 265():110667. PubMed ID: 37931433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botanically-Derived Δ
    Fitzpatrick JM; Hackett B; Costelloe L; Hind W; Downer EJ
    Molecules; 2022 Mar; 27(6):. PubMed ID: 35335126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
    Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
    PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabis and Neuropsychiatric Disorders: An Updated Review.
    Chayasirisobhon S
    Acta Neurol Taiwan; 2019 Jun; 28(2)():27-39. PubMed ID: 31867704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting the role of CB
    Li X; Hempel BJ; Yang HJ; Han X; Bi GH; Gardner EL; Xi ZX
    Eur Neuropsychopharmacol; 2021 Feb; 43():38-51. PubMed ID: 33334652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol skews biased agonism at cannabinoid CB
    Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
    Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanism and Cannabinoid Pharmacology.
    Schurman LD; Lu D; Kendall DA; Howlett AC; Lichtman AH
    Handb Exp Pharmacol; 2020; 258():323-353. PubMed ID: 32236882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
    Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
    Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
    Rao GK; Kaminski NE
    J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral effects of cannabinoid agents in animals.
    Chaperon F; Thiébot MH
    Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB
    Aviz-Amador A; Contreras-Puentes N; Mercado-Camargo J
    Comput Biol Chem; 2021 Dec; 95():107590. PubMed ID: 34700256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
    Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
    Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marijuana-Derived Cannabinoids Trigger a CB2/PI3K Axis of Suppression of the Innate Response to Oral Pathogens.
    Gu Z; Singh S; Niyogi RG; Lamont GJ; Wang H; Lamont RJ; Scott DA
    Front Immunol; 2019; 10():2288. PubMed ID: 31681262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-mediated effects of Δ
    Preteroti MW; Traboulsi H; Greiss P; Lapohos O; Fonseca GJ; Eidelman DH; Baglole CJ
    Immunol Cell Biol; 2023 Feb; 101(2):156-170. PubMed ID: 36510483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cannabinoids Effect on Bone Formation and Bone Healing.
    Raphael-Mizrahi B; Gabet Y
    Curr Osteoporos Rep; 2020 Oct; 18(5):433-438. PubMed ID: 32705630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol.
    Černe K
    Arh Hig Rada Toksikol; 2020 Mar; 71(1):1-11. PubMed ID: 32597140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells.
    Kozela E; Pietr M; Juknat A; Rimmerman N; Levy R; Vogel Z
    J Biol Chem; 2010 Jan; 285(3):1616-26. PubMed ID: 19910459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.